Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Sionna Therapeutics, Inc.NASDAQ: SION
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 23.4% from a year ago
Cash & equivalents stood at $63.32M at the end of Q1 FY2026, down 23.4% from a year earlier and up 8.3% from the prior quarter. Over 3 fiscal years it compounded at +2.2% a year.
Context
- Cash & equivalents amounted to 20.8% of total assets at the end of Q1 FY2026, down 1.6 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -23.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 58.45M USD
- Year-over-year change
- +54.7%
- 3-year CAGR
- +2.2%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 58.45M | +54.7% |
| FY2024 | 2024-12-31 | 37.79M | -1.9% |
| FY2023 | 2023-12-31 | 38.52M | -29.8% |
| FY2022 | 2022-12-31 | 54.84M | — |
Cash & Equivalents vs competitors
How SION compares with its peers on the latest reported figures
- SION's Mar 2026 cash & equivalents of $63.32M is the 7th highest of the 11 companies compared; the peer median is $106.11M.
- Its year-over-year change of -23.4% is the 8th highest of 11, against a peer median of +0.4%.
- Cash & equivalents amounts to 20.8% of total assets for SION, versus a peer median of 10.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $238.03M | +43.6% | +3.9% | 64.2% | |
| Sep 2026 | $212.84M | -21.9% | +218.0% | 42.1% | |
| Mar 2026 | $198.77M | -32.5% | +23.7% | 47.4% | |
| Sep 2026 | $163.8M | +97.0% | -30.7% | 10.9% | |
| Mar 2026 | $111.75M | +91.2% | -3.1% | 28.5% | |
| Sep 2026 | $100.46M | +55.0% | -53.2% | 8.5% | |
| Mar 2026 | $63.32M | -23.4% | +2.2% | 20.8% | |
| Mar 2026 | $51.83M | -29.7% | +0.6% | 5.0% | |
| Jun 2026 | $48.88M | -0.5% | +101.3% | 9.2% | |
| Mar 2026 | $31.21M | +1.3% | -10.9% | 6.2% | |
| Sep 2026 | $26.95M | -25.2% | -0.6% | 3.7% | |
| Peer median (excluding SION) | $106.11M | +0.4% | -0.0% | 10.0% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.